Mediclarum
Medicine guide

Meropenem

2 g · Injection

  • Prescription only
  • Penem Antibacterial
Active substance
Meropenem
Made by
Mylan Institutional LLC

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2024-12-25

What it is

Penem Antibacterial

Used for
  • 1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria…
The label’s usual adult dose

There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) intravenous bolus injection.

Full directions ↓
Do not take it if

Meropenem for injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams.

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
38other products contain Meropenem — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

  • 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae , in pediatric patients 3 months of age and older.
  • Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.
  • 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
  • When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
  • In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
  • Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only.
  • (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
  • (1.2)

From the official label · 2024-12-25 · DailyMed

How it works

From this product’s own US prescribing label.

Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration.

No accumulation of meropenem in plasma was observed with regimens using 1 gram administered every 6 hours in healthy volunteers with normal renal function.

Half-life1.5 h
Mostly cleared after≈ 7.5 hfive half-lives — our arithmetic
How it leaves the body

Meropenem is primarily excreted unchanged by the kidneys.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-12-25

Do not take it if

  • Meropenem for injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams.
  • Known hypersensitivity to product components or other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)lactams.
  • (4)

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • Pediatric patients 3 months of age and older with bacterial meningitis (2.1) Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Bacterial Meningitis and Normal Renal Function (2.1) Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Bacterial Meningitis 40 2 grams Every 8 hours Intravenous infusion is to be given over approximately 15 minutes to 30 minutes.
  • There is no experience with the use of Meropenem for Injection in pediatric patients with renal impairment.
  • 2.1 Recommended Dosage in Pediatric Patients 3 Months of Age and Older with Bacterial Meningitis For pediatric patients 3 months of age and older with bacterial meningitis, the Meropenem for Injection recommended dosage is 40 mg/kg every 8 hours (maximum dosage is 2 grams every 8 hours).
  • For pediatric patients weighing over 50 kg administer Meropenem for Injection at a dosage of 2 grams every 8 hours for bacterial meningitis.
  • Administer diluted Meropenem for Injection as an intravenous infusion over approximately 15 minutes to 30 minutes [see Dosage and Administration (2.2)] .
  • There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) intravenous bolus injection.
  • There is no experience with the use of Meropenem for Injection in pediatric patients with renal impairment [see Clinical Pharmacology (12.3)] .
  • 2.2 Preparation and Administration of Meropenem for Injection Preparation instructions for Intravenous Infusion (Reconstitution and Dilution) Reconstitute Meropenem for Injection vial (2 grams) with Sterile Water for Injection according to the instructions in Table 1 below.
  • Shake well to dissolve and let stand until clear.
  • Table 1:
  • Volume of Sterile Water for Injection for Reconstitution of Injection Vials Vial Size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 2 grams 40 mL 40 mL 50 mg/mL Add the resulting reconstituted solution to an intravenous container and further dilute with an appropriate infusion fluid [see Dosage and Administration (2.3) and (2.4)] .
  • Discard unused portion.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • When reconstituted, the solution varies from colorless to yellow depending on the concentration.
  • Do not use flexible container in series connections.
  • Administration Instructions for Meropenem Intravenous Infusion Solution After reconstitution and dilution of Meropenem for Injection, administer the appropriate dose of diluted Meropenem solution as an intravenous infusion over approximately 15 minutes to 30 minutes [see Dosage and Administration (2.1)] .
  • 2.3 Compatibility Compatibility of Meropenem for Injection with other drugs has not been established.
  • Meropenem for Injection should not be mixed with or physically added to solutions containing other drugs.
  • 2.4 Stability and Storage Reconstituted Solution with Sterile Water for Injection Use the reconstituted solution with Sterile Water for Injection immediately.
  • However, re-constituted solutions of Meropenem for Injection maintain satisfactory potency under the conditions described below.
  • Do not freeze reconstituted solutions of Meropenem for Injection.
  • Reconstituted Solution Diluted with Sodium Chloride Injection, 0.9 % Solutions prepared for infusion (meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) reconstituted with Water for Injection and further diluted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 2 hours at up to 5°C (41°F).
  • Reconstituted Solution Diluted with Dextrose Injection, 5 % Immediately use solutions (meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) reconstituted with Water for Injection and subsequently diluted with Dextrose Injection 5%.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams.
  • (5.1) Severe cutaneous adverse reactions have been reported in patients receiving meropenem for injection.
  • (5.2) Rhabdomyolysis:
  • If signs or symptoms of rhabdomyolysis are observed, discontinue meropenem for injection and initiate appropriate therapy.
  • (5.3) Seizures and other adverse CNS experiences have been reported during treatment.
  • (5.4) Co-administration of meropenem for injection with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures.
  • (5.5, 7.2) Clostridioides difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported.
  • Evaluate if diarrhea occurs.
  • (5.6) In patients with renal dysfunction, thrombocytopenia has been observed (5.9)
  • 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams.
  • These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.
  • There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam.
  • Before initiating therapy with meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens.
  • If an allergic reaction to meropenem for injection occurs, discontinue the drug immediately.
  • 5.2 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem for injection [see Adverse Reactions (6.2)] .
  • If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.
  • 5.3 Rhabdomyolysis Rhabdomyolysis has been reported with the use of meropenem [see Adverse Reactions (6.2)] .
  • If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, discontinue meropenem for injection and initiate appropriate therapy.
  • 5.4 Seizure Potential Seizures and other adverse CNS experiences have been reported during treatment with meropenem for injection.
  • These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function [see Adverse Reactions (6.1) and Drug Interactions (7.2)] .
  • During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with the overall seizure rate being 0.7% (based on 20 patients with this adverse event).
  • All meropenem-treated patients with seizures had pre-existing contributing factors.
  • Among these included a prior history of seizures or CNS abnormality and concomitant medications with seizure potential.
  • Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity.
  • Continue anti-convulsant therapy in patients with known seizure disorders.
  • If focal tremors, myoclonus, or seizures occur, evaluate neurologically, placed on anti-convulsant therapy if not already instituted, and reexamine the dosage of meropenem for injection to determine whether it should be decreased or discontinued.
  • 5.5 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended.
  • Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction.
  • Consider administration of antibacterial drugs other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.
  • If administration of meropenem for injection is necessary, consider supplemental anti-convulsant therapy [see Drug Interactions (7.2)] .
  • 5.6 Clostridioides difficile - associated Diarrhea Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including meropenem for injection, and may range in severity from mild diarrhea to fatal colitis.
  • Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
  • C. difficile produces toxins A and B which contribute to the development of CDAD.
  • Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
  • CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
  • Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
  • If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
  • Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
  • 5.7 Development of Drug-Resistant Bacteria Prescribing meropenem for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
  • 5.8 Overgrowth of Nonsusceptible Organisms As with other broad-spectrum antibacterial drugs, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms.
  • Repeated evaluation of the patient is essential.
  • If superinfection does occur during therapy, appropriate measures should be taken.
  • 5.9 Thrombocytopenia In patients with renal impairment, thrombocytopenia has been observed but no clinical bleeding reported [see Dosage and Administration (2.2), Adverse Reactions (6.1), and Clinical Pharmacology (12.3)] .
  • 5.10 Potential for Neuromotor Impairment Alert patients receiving meropenem for injection on an outpatient basis regarding adverse events such as seizures,delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment.
  • Until it is reasonably well established that meropenem for injection is well tolerated, advise patients not to operate machinery or motorized vehicles [see Adverse Reactions (6.1)] .

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • IN SPECIFIC POPULATIONS
  • 8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women.
  • No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively.
  • In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison (see Data ) .
  • The background risk of major birth defects and miscarriage for the indicated population is unknown.
  • All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
  • In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
  • Data Meropenem administered to pregnant rats during organogenesis (Gestation Day 6 to Gestation Day 17) in intravenous doses of 240, 500, and 750 mg/kg/day was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity.
  • The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/day (equivalent to approximately 2.4 times the MRHD of 1 gram every 8 hours based on body surface area comparison).
  • Meropenem administered intravenously to pregnant Cynomolgus monkeys during organogenesis from Day 20 to 50 after mating at doses of 120, 240, and 360 mg/kg/day did not produce maternal or fetal toxicity at the NOAEL dose of 360 mg/kg/day (approximately 2.3 times the MRHD based on body surface area comparison).
  • In a peri-postnatal study in rats described in the published literature1, intravenous meropenem was administered to dams from Gestation Day 17 until Lactation Day 21 at doses of 240, 500, and 1000 mg/kg/day.
  • There were no adverse effects in the dams and no adverse effects in the first generation offspring (including developmental, behavioral, and functional assessments and reproductive parameters) except that female offspring exhibited lowered body weights which continued during gestation and nursing of the second generation offspring.
  • Second generation offspring showed no meropenemrelated effects.
  • The NOAEL value was considered to be 1000 mg/kg/day (approximately 3.2 times the MRHD based on body surface area comparisons).
  • 8.2 Lactation Risk Summary Meropenem has been reported to be excreted in human milk.
  • No information is available on the effects of meropenem on the breast-fed child or on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for meropenem for injection and any potential adverse effects on the breast-fed child from meropenem for injection or from the underlying maternal conditions.
  • 8.4 Pediatric Use The safety and effectiveness of Meropenem for Injection have been established for pediatric patients 3 months of age and older for the treatment of bacterial meningitis caused by Haemophilus influenzae , Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae , and the information on this use is discussed throughout the labeling.
  • The safety and effectiveness of Meropenem for Injection have not been established in pediatric patients younger than 3 months of age.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

  • Co-administration of meropenem for injection with probenecid inhibits renal excretion of meropenem and therefore Meropenem for Injection is not recommended.
  • (7.1) The concomitant use of Meropenem for Injection and valproic acid or divalproex sodium is generally not recommended.
  • Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium (5.4, 7.2)
  • 7.1 Probenecid Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem.
  • Co-administration of probenecid with meropenem is not recommended.
  • 7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.
  • The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.
  • Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid.
  • If administration of meropenem for injection is necessary, then supplemental anti-convulsant therapy should be considered [see Warnings and Precautions (5.4)] .

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

  • In mice and rats, large intravenous doses of meropenem (2200 mg/kg to 4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
  • Intentional overdosing of meropenem for injection is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function.
  • The largest dose of meropenem administered in clinical trials has been 2 grams given intravenously every 8 hours.
  • At this dosage, no adverse pharmacological effects or increased safety risks have been observed.
  • Limited postmarketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction.
  • Consider symptomatic treatments.
  • In individuals with normal renal function, rapid renal elimination takes place.
  • Meropenem and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.

Quoted from the official label, section “Overdosage”.

Side effects

  • The following are discussed in greater detail in other sections of labeling:
  • Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] Rhabdomyolysi s [see Warnings and Precautions (5.3)] Seizure Potential [see Warnings and Precautions (5.4)] Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid [see Warnings and Precautions (5.5)] Clostridioides difficile – Associated Diarrhea [see Warnings and Precautions (5.6)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.7)] Overgrowth of Nonsusceptible Organisms [see Warnings and Precautions (5.8)] Thrombocytopenia [see Warnings and Precautions (5.9)] Potential for Neuromotor Impairment [see Warnings and Precautions (5.10)] Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis (6.1) To report SUSPECTED ADVERSE REACTIONS, Mylan at 1-877-446-3679(1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • Adverse Reactions in Pediatric Patients with Bacterial Meningitis Meropenem for injection was studied in 321 pediatric patients (3 months to less than 17 years of age) with bacterial meningitis at a dosage of 40 mg/kg every 8 hours.
  • The most common adverse reactions and their rates of occurrence were as follows:
  • Diarrhea 4.7% Rash (mostly diaper area moniliasis) 3.1% Oral Moniliasis 1.9% Glossitis 1% In these studies, the rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem for injection and those who received comparator agents (either cefotaxime or ceftriaxone).
  • In the meropenem for injection-treated group, 12/15 patients with seizures had late onset seizures (seizures that occurred on day 3 or later) versus 7/20 patients in the comparator arm.
  • The meropenem for injection group had a statistically higher number of patients than the comparator with transient elevation of liver enzymes.
  • Adverse Reactions from Studies of Meropenem for Injection in Other Serious Bacterial Infections (not bacterial meningitis) The following adverse reactions occurred in studies of 2,904 immunocompetent adult patients who received meropenem for injection (500 mg or 1 gram every 8 hours) for the treatment of other serious bacterial infections (not bacterial meningitis).
  • This meropenem for injection product is indicated only for the treatment of bacterial meningitis caused by certain organisms in pediatric patients 3 months of age and older [see Indications and Usage (1.1)] .
  • Many patients in these studies were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies.
  • In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with meropenem for injection.
  • Deaths in 5 patients were assessed as possibly related to meropenem for injection; 36 (1.2%) patients had meropenem for injection discontinued because of adverse events.
  • Local Adverse Reactions Local adverse reactions that were reported with meropenem for injection were as follows:
  • Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).
  • Systemic Adverse Reactions Systemic adverse reactions that occurred in greater than 1% of the meropenem for injection-treated patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%).
  • Additional systemic adverse reactions that occurred in less than or equal to 1% but greater than 0.1% of the meropenem for injection-treated patients are listed below within each body system in order of decreasing frequency:
  • Bleeding Event s :
  • gastrointestinal hemorrhage (0.5%), melena (0.3%), epistaxis (0.2%), hemoperitoneum (0.2%).
  • Body as a Whole:
  • pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, pelvic pain Cardiovascular:
  • heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension, syncope Digestive System:
  • oral moniliasis, anorexia, cholestatic jaundice/jaundice, flatulence, ileus, hepatic failure,dyspepsia, intestinal obstruction Hemic/Lymphatic:
  • anemia, hypochromic anemia, hypervolemia Metabolic/Nutritional:
  • peripheral edema, hypoxia Nervous System:
  • insomnia, agitation, delirium, confusion, dizziness, seizure, nervousness, paresthesia,hallucinations, somnolence, anxiety, depression, asthenia Respiratory:
  • respiratory disorder, dyspnea, pleural effusion, asthma, cough increased, lung edema Skin and Appendages:
  • urticaria, sweating, skin ulcer Urogenital System:
  • dysuria, kidney failure, vaginal moniliasis, urinary incontinence Laboratory Abnormalities Laboratory abnormalities that occurred in greater than 0.2% of the meropenem for injection-treated patients were as follows:
  • Hepatic:
  • increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, lactate dehydrogenase (LDH), and bilirubin Hematologic:
  • increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cell (WBC), shortened prothrombin time and shortened partial thromboplastin time, leukocytosis, hypokalemia Renal:
  • increased creatinine and increased blood urea nitrogen (BUN) Urinalysis:
  • presence of red blood cells
  • 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of meropenem, including meropenem for injection.
  • Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • Worldwide post-marketing adverse reactions not otherwise listed under the Clinical Trials Experience subsection [see Adverse Reactions (6.1)] and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity.
  • Blood and Lymphatic System Disorders :
  • agranulocytosis, neutropenia, and leukopenia; a positive direct or indirect Coombs test, and hemolytic anemia.
  • Immune System Disorders: angioedema.
  • Skin and Subcutaneous Disorders:
  • Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and acute generalized exanthematous pustulosis.
  • Musculoskeletal Disorders: rhabdomyolysis

Quoted from the official label, section “Adverse Reactions”.

Strengths and forms

  • FORMS AND STRENGTHS Meropenem for Injection, USP 2 g/vial:
  • 2 grams of meropenem as a white to slight yellow crystalline powder in a single-dose vial for reconstitution.
  • Meropenem for Injection:
  • 2 grams of meropenem as a powder in a single-dose vial for reconstitution (3)

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

  • Meropenem for Injection, USP is supplied in a single-dose vial containing meropenem as awhite to slight yellow crystalline powder powder to deliver 2 grams of meropenem for intravenous administration after reconstitution.
  • The dry powder should be stored at 20°C to 25ºC (68°F to 77ºF).
  • Brief exposure to 15°C to 30°C (59°F to 86°F) is permitted [see USP Controlled Room Temperature].
  • NDC 72078-081-00 2 gram single-dose injection vial NDC 72078-081-06 2 gram single-dose injection vial packaged in a carton of 6 The container closure is not made with natural rubber latex.

Quoted from the official label, section “How Supplied”.

What is in it

  • Meropenem for Injection, USP contains meropenem a synthetic carbapenem antibacterial. Meropenem is (4R,5S,6S)-3[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept2-ene-2-carboxylic acid trihydrate. Its empirical formula is C17H25N3O5S
  • 3H2O with a molecular weight of 437.52. Its structural formula is:
  • Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether. Meropenem for Injection, USP is a white to slight yellow crystalline powder for intravenous administration. Each vial contains meropenem equivalent to 2 grams and 416 mg of sodium bicarbonate, anhydrous. When re-constituted as instructed Meropenem for Injection, USP will deliver 2 grams of meropenem (on anhydrous basis) and approximately 180 mg of sodium as sodium carbonate (7.8 mEq) [see Dosage and Administration (2.2)] . The solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3. Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (3)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 3 of 3

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Spain4 matching products

Every strength and form (37)

CanadaNo exact match for this strength and form

Every strength and form (4)

Details

Made byMylan Institutional LLC
Active substanceMeropenem
Used inAntibiotics, antivirals and antifungals taken into the body
Strength2 g
FormInjection
RouteIntravenous
Packs6 INJECTION in 1 CARTON
NDC72078-081

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

39 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Meropenem500 mg/20mLPrescription onlyInjection Hikma Pharmaceuticals USA Inc. · MeropenemMeropenem1 g/30mLPrescription onlyInjection Hikma Pharmaceuticals USA Inc. · MeropenemMeropenem500 mg/10mLPrescription onlyInjection, Powder, for Solution Hikma Pharmaceuticals USA Inc. · MeropenemMeropenem1 g/20mLPrescription onlyInjection, Powder, for Solution Hikma Pharmaceuticals USA Inc. · MeropenemMeropenem500 mg/10mLPrescription onlyInjection, Powder, for Solution Hospira, Inc. · MeropenemMeropenem1 g/20mLPrescription onlyInjection, Powder, for Solution Hospira, Inc. · Meropenem

See every product with Meropenem